China IVD Regulatory Affairs Outsourcing

Bringing in vitro diagnostic (IVD) devices to the Chinese market is complex, and often overwhelming without the right support. From mandatory local testing to evolving technical guidelines and regulatory changes, navigating China’s National Medical Products Administration (NMPA) approval process demands specialized knowledge.

What's more, China’s regulatory environment requires in-country representation, Chinese-language documentation, and close coordination with local testing labs and authorities. For IVD manufacturers, this creates three key challenges: how to accelerate market access whilst ensuring full regulatory compliance and keeping operational costs under control.

Outsourcing regulatory affairs to a trusted local partner such as Cisema offers a practical and strategic solution.

China NMPA IVD Registration
Medical Device Registration Indonesia
Three professional women standing by a window, smiling and holding coffee cups during a casual conversation.

Why Outsource Regulatory Affairs for IVDs in China?

At Cisema, we serve as your dedicated regulatory affairs partner in China, helping you register, launch, and maintain your IVD devices in full compliance with NMPA regulations. With decades of experience, our experts manage your regulatory journey from start to finish, reducing your internal burden and helping you stay ahead of changes.

We act as your external regulatory team, managing everything from product registration to post-market surveillance (PMS), so you can focus on innovation and growth.

Key Benefits of Outsourcing with Cisema's Regulatory Experts

Local Expertise with Global Insight

Our deep understanding of Chinese and international regulatory frameworks ensures compliance strategies that fit your business goals.

Faster Market Entry

Avoid delays and streamline the approval process with our expert support and local testing coordination.

Cost-Efficient Operations

Minimize internal staffing needs and lower your regulatory overhead.

Focus on Core Capabilities

Free your internal teams from regulatory complexity to concentrate on R&D, production, and commercialization.

Access to Specialist Knowledge

Our team offers up-to-date insights on NMPA requirements and regulatory standards, helping you make informed decisions and avoid costly missteps.

Compliance & Risk Reduction

We help build compliant quality management systems, support audits, and manage documentation to reduce regulatory risk.

Independent & Transparent Service

We’re not a distributor. As a neutral third party, we work exclusively in your interest.

Our IVD Regulatory Outsourcing Services

Cisema offers end-to-end regulatory support tailored for IVD manufacturers seeking to enter or expand the Chinese market:

NMPA Registration Support

Type testing at NMPA-authorized labs
Clinical evaluation and dossier preparation
Submission for Class II and III IVDs
Pathways for innovative or urgent-use diagnostics

Legal Agent & In-Country Representation

Official Legal Agent with NMPA
Communication with Chinese regulatory authorities
Ongoing license maintenance and renewals

Post-Market Services

Adverse event monitoring and reporting
Change management and license updates
UDI compliance and tracking system setup

Quality & Compliance Management

Implementation of Chinese GMP for IVDs
Internal audits and CAPA planning
Risk management system development

Labeling & IFU Review

Chinese-language content verification
Barcode and UDI alignment
Format and regulatory review

Documentation & Control

SOPs, QMS documentation, and lifecycle management
Alignment with current NMPA regulations and expectations

Request a Proposal for IVD Regulatory Outsourcing Services

Let Cisema help turn your plans into reality.

Request Proposal

Useful Articles

View More

China Medical Device and IVD Registration FAQs: What Foreign Manufacturers Need to Know About NMPA Requirements

Get answers to common China medical device and IVD registration questions, from NMPA classification rules to testing and renewal requirements.

April 23, 2026
China Medical Device and IVD Registration FAQs: What Foreign Manufacturers Need to Know About NMPA Requirements
China Medical Device and IVD Registration FAQs: What Foreign Manufacturers Need to Know About NMPA Requirements

China IVD Risk Classification Explained: How NMPA Class Shapes Registration Pathways

Learn how China IVD risk classification works under NMPA rules and see common compliance pitfalls to avoid.

April 23, 2026
China IVD Risk Classification Explained: How NMPA Class Shapes Registration Pathways
China IVD Risk Classification Explained: How NMPA Class Shapes Registration Pathways
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and outsourcing solutions to help your business thrive.

China IVD Product Approvals

We guide you through every step of the China IVD registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal China entry pathway, and helping you through the whole process.

Learn more

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

NMPA IVD Type Testing

Our on-site test engineers coordinate and supervise type tests of your IVDs in NMPA-accredited laboratories.

Learn more

Drug Device Combination Products

We assist with the classification, authorization, and compliance of combination products in China, whether drug or device led.

Learn more

China IVD Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

Learn more

IVD PMS & Vigilance

The NMPA is placing greater focus on PMS such as more in-China sampling inspections and regular standard changes.

Learn more

Latest Insights

View More

China NMPA Issues 2026 Medical Device Industry Standards Development and Revision Plan

China’s National Medical Products Administration has issued its 2026 medical device standards plan, introducing 80+ new and revised standards

April 23, 2026
China NMPA Issues 2026 Medical Device Industry Standards Development and Revision Plan

China NMPA Clears 104 Innovative Medical Devices for Special Review in 2025

Learn about the 104 products China’s NMPA admitted into the Special Review Procedure for Innovative Medical Devices in 2025.

March 18, 2026
China NMPA Clears 104 Innovative Medical Devices for Special Review in 2025
China NMPA Clears 104 Innovative Medical Devices for Special Review in 2025

Hong Kong Launches Pre-NDA Meetings Under the “1+” Drug Registration Mechanism

Hong Kong’s Department of Health introduces Pre-NDA meetings to streamline new drug registrations under the “1+” mechanism.

April 15, 2026
Hong Kong Launches Pre-NDA Meetings Under the “1+” Drug Registration Mechanism
Hong Kong Launches Pre-NDA Meetings Under the “1+” Drug Registration Mechanism

Hong Kong DH Mandates Medical Device Listing for Public Procurement by March 2026

The Department of Health has mandated MDACS listing for public procurement eligibility — see which devices are affected and how to prepare.

April 15, 2026
Hong Kong DH Mandates Medical Device Listing for Public Procurement by March 2026
Hong Kong DH Mandates Medical Device Listing for Public Procurement by March 2026

China Medical Device Imports Remain Stable in H1 2025

China’s H1 medical device imports reached approx. USD 24 billion, showing stable demand amid shifts in key categories and sourcing countries.

March 18, 2026
China Medical Device Imports Remain Stable in H1 2025
China Medical Device Imports Remain Stable in H1 2025

China’s NMPA Releases Draft Adjustments to the IVD Classification Catalogue

NMPA issues draft changes to China’s IVD Classification Catalogue, adding new risk classes and technology platforms.

March 18, 2026
China’s NMPA Releases Draft Adjustments to the IVD Classification Catalogue
China’s NMPA Releases Draft Adjustments to the IVD Classification Catalogue
Previous
Previous

Get in Touch with Our Life Sciences Team

With over 20 years of experience and a proven track record, Cisema is trusted by startups and global IVD leaders alike to manage China regulatory affairs with efficiency and precision.

Request Proposal